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Recent studies show that in Alzheimer’s disease (AD), alterations in neurogenesis contribute to the neurodegenerative process.
Neurodegeneration in AD has been associated with aberrant signaling through the cyclin-dependent kinase-5 (CDK5) pathway
via its activators p35/p25; however, the role of CDK5 in the mechanisms of defective adult neurogenesis in AD is unknown. First,
to study AD-like abnormal activation of CDK5 signaling in an in vitro model of neurogenesis, neuronal progenitor cells (NPCs)
were infected with a viral vector expressing p35, and exposed to amyloid-b protein (Ab1 42). These conditions resulted in
impaired maturation and neurite outgrowth in vitro, and these effects were reversed by pharmacological or genetic inhibition of
CDK5.Similarly, neurogenesis was impaired in a transgenic mouse model of AD that expresses high levels of amyloidprecursor
protein (APP), and this effect was reversed intransgenic mice crossed witha CDK5 heterozygous-deﬁcient mouse line. Asimilar
rescue effect was observed in APP transgenic mice treated with Roscovitine, a pharmacological inhibitor of CDK5. Taken
together,thesedatasuggestthattheCDK5signalingpathwayhasacriticalroleinmaintainingtheintegrityofNPCsandneuronal
maturation in the adult hippocampus. Moreover, potential therapeutic approaches could focus on modulating the aberrant
activity of CDK5 to target the neurogenic and neurodegenerative alterations in AD.
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During aging and in the progression of Alzheimer’s disease
(AD), synaptic plasticity and neuronal integrity are disturbed.
1
In AD, this has been linked to aberrant activation of cyclin-
dependent kinase-5 (CDK5) and its activators p35 and p25,
2,3
and with increased levels of CDK5 in the brains of AD
patients.
4
CDK5 is the predominant CDK found in the brain, is highly
expressed in neurons, and has an important role in synaptic
plasticity, dendritic growth,
5,6 and neuronal development
7 in
mature neurons. Many of the diverse functions of CDK5
activity occur via phosphorylation of numerous substrates,
including cytoskeletal proteins (e.g., nestin, doublecortin
(DCX)), synaptic proteins (e.g., synapsin I, PSD95), and
transcription factors (e.g., MEF2). Unlike canonical CDK
signaling, CDK5 is activated by the non-cyclin proteins p35
andp39.
8AlthoughCDK5activationviap35isassociatedwith
physiological activity of CDK5, the truncated p25 form – which
in AD can be generated by amyloid-b (Ab)-mediated calpain
cleavage of p35
9– abnormally stimulates CDK5 signaling and
leads to aberrant phosphorylation of substrates such as tau.
10
This process contributes to neurotoxicity and cell death in AD,
possiblyviaimpropercellcyclere-entryinmatureneurons.
7,11
In addition to alterations in synaptic plasticity and neuronal
cell survival in AD, recent studies have revealed that the
neurodegenerative process in this disorder might include
dysregulation of adult neurogenesis.
12–14 In the brains of AD
patients and in animal models, there may be a decrease in the
generation of new neurons from neural progenitor cells
(NPCs) in the subgranular zone (SGZ) of the adult hippo-
campal dentate gyrus (DG).
14–18 Consistent with these
observations, we have recently found that markers of
neurogenesis are reduced in a stage-dependent manner in
the hippocampus of patients with AD.
19
Although the mechanisms of neurogenesis in the fetal brain
have been extensively studied, less is known about the
signaling pathways regulating adult neurogenesis and their
role in neurodegenerative disorders. During embryogenesis,
CDK5 is a critical factor in neuronal development
20 and
migration.
21 Homozygous ablation of the Cdk5 gene is lethal
in mice;
21,22 however, heterozygous knockdown of one gene
copy results in relatively normal brain development.
22 More
recently, CDK5 has been shown to be essential for adult
neurogenesis.
6,23 In one in vivo model, conditional ablation of
the Cdk5 gene resulted in reduced numbers of immature SGZ
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isms.
23 In a separate study, retrovirus-mediated inhibition of
CDK5 activity using a dominant-negative kinase mutant
(DNcdk5) altered dendritic morphology and orientation of
hippocampal NPCs.
6 These studies suggest that physio-
logical CDK5 activity is critical for maturation of progenitor
cells in the adult hippocampus; however, the effects of
abnormal CDK5 activity associated with the pathogenesis of
AD have not been explored in the adult neurogenic niches.
It is possible that the alterations in adult hippocampal
neurogenesis associated with AD might be related to
abnormal CDK5 activity. In support of this possibility, we
have previously shown in a mouse model of AD that a
neurotrophic therapy that promotes neurogenesis also mod-
ulates CDK5 activity.
18,24 Moreover, in other in vitro models of
AD, Ab has been shown to impair neurogenesis via calpain
activation and p35 dysregulation;
25 however, the effects of
CDK5 activation onadult neurogenesis remainunclear. In this
study we investigated the role of aberrant CDK5 signaling in
defectiveneurogenesisinAD,andwereportthatininvitroand
in vivo models, deﬁcits in neuronal maturation can be
reversed by genetic or pharmacological modulation of CDK5.
Results
Characterization of the CDK5 signaling pathway in an
in vitro model of adult hippocampal neurogenesis. To
begin to investigate the role of CDK5 in adult neurogenesis in
AD, we ﬁrst examined the expression patterns of the CDK5
pathway, and markers of differentiation, in an in vitro
model of adult hippocampal neurogenesis. For this purpose,
NPCs derived from adult rat hippocampus were differentiated
toward a neuronal phenotype over a period of 4 days
essentially as previously described.
26 (Supplementary
Figure 1A).
NPCs were grown in NPC differentiation media for 4 days
and analyzed by western blot, quantitative real-time PCR
(qRT-PCR), and immunocytochemistry. By western blot, the
levels of early glial (S100) and immature neuronal markers
(b-III tubulin (Tuj1) and DCX) increased during differentiation,
and the levels of progenitor cell markers (nestin, proliferating
cell nuclear antigen (PCNA), and brain lipid-binding protein
(BLBP)) decreased. Expression of markers of other mature
lineages (glial ﬁbrillary acidic protein (GFAP), astroglial
marker) remained low (Supplementary Figure 1B). Immuno-
blot and qRT-PCR analyses showed that protein and mRNA
expression levels of CDK5 increased approximately twofold
during differentiation, and levels of p35/p25 remained
relatively low at all stages studied (Supplementary Figure
1B). During neuronal induction, cells acquired a neuron-like
phenotype (Supplementary Figure 1C–E). Immunocytochem-
ical analysis conﬁrmed that levels of CDK5 and b-III tubulin
increased concurrently over the 4-day differentiation period
(Supplementary Figure 1F–K).
Modeling AD-associated aberrant activation of CDK5 in
adult neurogenesis in vitro. Given the potential role of
abnormal CDK5 activity in neurodegeneration in AD,
2–4 we
sought to develop an in vitro model to examine whether this
kinase might also contribute to defective neurogenesis in
AD models. For this purpose, we stimulated the CDK5 pathway
in the adult rat hippocampal NPC model by expressing the
CDK5 activator, p35, utilizing a viral vector. Infection of NPCs
with an adenoviral (adv) construct expressing p35 resulted in
high levels of p35 expression after 4 days of differentiation,
and generation of the p25 fragment was detectable with high
levels of p35 expression (Figure 1a).
Phase contrast microscopy of live cell cultures showed no
signiﬁcant morphological differences in adv-p35-infected
cultures compared with uninfected or adv-GFP-infected
controls (Figures 1b–d). As Ab has been shown to abnormally
regulate the activity of this pathway, following adv-p35
infection, cultures were treated with 1mMA b1 42 for 24h
(Figures 1e–g). Compared with infection with adv-p35 alone,
combined p35/Ab treatment resulted in an B20% increase in
p25 immunoreactivity, and a 30–40% reduction in p35
immunoreactivity (Figure 1a). This supports the contention
that combined p35/Ab treatment promotes cleavage of p35
and generation of the p25 fragment. Although the production
of p25 is associated with neurotoxicity in mature neurons, no
signiﬁcant cell toxicity was detected in the cultured NPCs
under these conditions (Figure 1h). This allowed subsequent
analyses to focus on the effects of aberrant CDK5 activity on
cell maturation. Analysis of kinase activity conﬁrmed that
in cells expressing p35 or treated with Ab alone, or in
combination, CDK5 activity was signiﬁcantly increased
compared with controls (Figure 1i).
Abnormal activation of CDK5 signaling impairs NPC
maturation in vitro. Under baseline conditions, by the end
of the 4-day differentiation period, the majority (490%) of
NPC-derived progeny were immunopositive for b-III-tubulin
(Tuj1) (Figures 2a–c, Supplementary Figure 1H), suggesting
that these cells represent predominantly immature neurons.
In order to determine whether activation of CDK5 was
associated with any measurable differences in neuronal
maturation, neurite outgrowth was assessed in p35/Ab-
treated NPC-derived neural progeny (Figures 1j–n). b-
Tubulin immunoﬂuorescence and neurite outgrowth studies
revealed that p35 and Ab treatment alone or in combination
resulted in shorter processes in NPC-derived neural progeny
compared with vehicle-treated controls (Figures 1j–n);
however, other controls for Ab (reverse Ab42 1 peptide)
and aggregating proteins (transthyretin (TTR)) had no
signiﬁcant effects on neurite outgrowth (not shown).
To further characterize the effects of CDK5 activation with
p35/Ab, double-labeling immunocytochemical analysis was
performed (Figure 2). Immunolabeling with an antibody
against p35/p25 conﬁrmed that p35 was expressed at high
levels in 495% of the adv-p35-infected cells after 4 days
under differentiating conditions (Figure 2h). In cultures
exposed to p35/Ab, NPC-derived neural progeny displayed
considerable co-immunoreactivity for markers of neuronal
lineage (Tuj1 and DCX) and progenitor cell markers (nestin)
(Figures 2j–r). Although in vector-infected, vehicle-treated
control cultures, B10% of cells coexpressed b-III tubulin and
nestin, in p35/Ab-treated progeny, this proportion was
increased to 30% (Figure 2s). This suggests that the neuronal
maturation process under these conditions may be impaired,
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Cell Death and Diseaseresulting in hybrid-like cells arrested in an early phase of
neuronal development. These results support the possibility
that constitutive activation of CDK5 signaling might promote
the generation of cells that are unable to fully complete
neuronal maturation.
Pharmacological inhibition of abnormal CDK5 activity,
or siRNA knockdown of CDK5, rescues neuronal
maturation in NPC-derived neural progeny. In order to
determine whether CDK5 contributes directly to alterations in
neuronal maturation (Figure 1), we used a pharmacological
inhibitor of CDK5 (Roscovitine), or an siRNA-based
approach, to inhibit CDK5 activity or expression,
respectively. First, to conﬁrm that these conditions were not
overtly toxic, and to characterize the efﬁcacy of CDK5 siRNA
(siCDK5) treatment in this system, we performed a series of
control experiments with NPCs treated on day 2 of
differentiation with Roscovitine or siCDK5 (Supplementary
Figure 2). Following Roscovitine treatment, CDK5 and p35
protein levels were comparable with vehicle-treated controls
(Supplementary Figure 2A), and these conditions showed no
signiﬁcant toxicity (Supplementary Figure 2B). Western blot,
qRT-PCR, and LDH assays demonstrated that transfection
with siCDK5 resulted in a marked reduction in CDK5 protein
and mRNA levels (B50%) without signiﬁcant toxicity
(Supplementary Figures 2C–E). Immunocytochemical
analysis conﬁrmed that CDK5 levels were signiﬁcantly
reduced in differentiating NPCs transfected with siCDK5
(Supplementary Figures 2F–H).
Next, we sought to determine whether pharmacological or
genetic inhibition of CDK5 might protect against the matura-
tion defects observed in NPC-derived neural progeny
exposed to p35/Ab. For this purpose, on day 2 of neuronal
induction, differentiating NPCs were pretreated with Roscov-
itine, or transfected with siCDK5 for 6h, followed by infection
with adv-p35, and Ab treatment (Figure 3). Neurite outgrowth
studies of b-tubulin-positive processes revealed that modulat-
ing CDK5 with Roscovitine or siCDK5 reversed the neurite
outgrowth deﬁcits observed after p35/Ab treatment (Figures
3a–g). Taken together, these results support the possibility
that AD-related aberrant activation of CDK5 signaling impairs
the maturation of adult hippocampal NPCs, andthis effect can
be reversed by modulation of CDK5 by pharmacological or
genetic means.
Alterations in neurogenesis in APP transgenic mice are
rescued by knockdown of CDK5 expression. To further
elucidate the role of AD-related aberrant CDK5 activation in
adult neurogenesis in vivo, we ﬁrst characterized the
expression patterns of members of the CDK5 signaling
pathway in the DG of a transgenic (tg) mouse line expressing
high levels of neuronal amyloid precursor protein (APP). We
have previously shown that hippocampal neurogenesis is
impaired in the brains of these animals.
19,24 In support of a
Figure 1 Characterization of an in vitro model of adult neurogenesis in AD, and impaired neurite outgrowth with aberrant CDK5 activation. Differentiating NPCs were
infectedatday2withanadenoviralvectorexpressingp35orGFPasacontrol,and24hlater,cellswereexposedto1mMAb1 42.Cellswereanalyzedbylivecellmicroscopy,
or lysed for immunoblot analysis, or brieﬂy extracted, and then ﬁxed with glutaraldehyde and processed for b-tubulin immunoﬂuorescence. (a) Immunoblot analysis of the
expression levels of CDK5,p35/p25, b-III-tubulin(Tuj1), GFP, and actin (loading control) in NPC-derived neural progenyexpressing adenovirus-delivered p35 or GFP(vector
control) and treated with Ab1 42 for 24h. Graph showing quantitative analysis of p35/p25 immunoreactivity demonstrates increased p25 generation in p35-expressing cells
after Ab treatment. *Nonspeciﬁc immunoreactive band detected with the p35/p25 antibody. (b–g) Live cell imaging showing the morphology of NPC-derived neural progeny
expressingp35orGFPcontrolandtreatedwithAb.(h)Nosigniﬁcantcytotoxicity(measuredbyLDHassay)wasdetectedincellsinfectedwithp35adenovirusorGFPcontrol,
orwithAbtreatmentaloneorincombinationwithp35expression.(i)IncreasedkinaseactivityofCDK5inp35andAbaloneandp35/Ab-treatedNPC-derivedneuralprogeny.
(j–m) Compared with vehicle-treated controls (Ctrl), shorter b-tubulin-immunoreactive neurites were detected in NPC-derived neural progeny with p35 or Ab treatment alone
or in combination.Cell nucleiwere co-stained with DAPI reagent. (n) Quantitativeimage analysisshowingreduced neurite lengths in NPC-derived neural progeny with p35 or
Ab treatment alone or in combination. Scale bar¼10mm. *Po0.05 compared with vehicle-treated controls by one-way ANOVA with post hoc Dunnett’s test (N¼3).
**Po0.01 compared with vehicle-treated controls by one-way ANOVA with post hoc Dunnett’s test (N¼3)
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Cell Death and Diseaserole for CDK5 in the adult hippocampus, double-labeling
immunocytochemical analyses demonstrated that APP,
CDK5, and p35 were expressed in the DG of APP tg mice
(Figures 4a–i). Moreover, CDK5 was detected in cells
surrounding and within a subset of SGZ cells that are
immunopositive for the developing neuronal marker DCX
(Figures 4j–l).
To investigate whether there were any alterations in CDK5
signaling in the hippocampus of APP tg mice, additional
immunohistochemical studies were performed. Compared
Figure 2 Morphological and maturation alterations in NPC-derived neural progeny expressing p35 and treated with Ab. Differentiating NPCs were infected with an
adenoviral vector expressing p35 or vector control on day 2 of differentiation, and then treated with 1mMA b or vehicle control on day 3 for 24h, followed by ﬁxation with
paraformaldehyde.Sampleswereprocessedfordouble-immunolabelingwithantibodiesagainstp35andmarkersofproliferativeandneuronaldifferentiationstatus(neuronal,
b-III tubulin (Tuj1), and doublecortin (DCX); progenitor cells, nestin). (a–f) Double-labeling analysis with Tuj1 and p35 antibodies in vector-infected NPC-derived neural
progeny treated with vehicle control (a–c)o rA b (d–f) for 24h. (g–l) Double-labeling analysis with Tuj1 and p35 antibodies in p35-expressing NPC-derived neural progeny
treated with vehicle control (g–i)o rA b (j–l) for 24h. (j–r) In combined p35/Ab-treated cultures, progeny acquired an abnormal stellate morphology and cells were
co-immunoreactive for markers of proliferation stages (nestin) and neuronal (Tuj1 and DCX) lineage (arrows). (s) Quantitative analysis of proportion of NPC-derived neural
progeny co-labeled with Tuj1 and nestin antibodies. Scale bar¼15mm. *Po0.05 compared with vehicle-treated controls by one-way ANOVA with post hoc Dunnett’s
test (N¼3)
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Cell Death and Diseasewith non-tg littermate controls, CDK5 (Figures 5a, c, and e)
and p35/p25 (Figures 5f, h, and j) immunoreactivity were
increasedintheDGofAPPtgmice.Furthermore,immunoblot
analysis showed that levels of phosphorylated CDK5 (Tyr15)
– a modiﬁcation that upregulates CDK5 activity,
27 – were
increased in the brains of APP tg mice compared with non-tg
controls (Supplementary Figures 3A and B). Consistent with
previous studies,
17–19 there was a reduction in the numbers of
DCX-positive (Figures 5k, m, and o) and 5-bromo-2-deoxy-
uridine (BrdU)-positive (Figures 5p, r, and t) cells in the DG of
APP tg mice compared with non-tg controls.
In addition to the reduction in the total numbers of DCX-
positive cells in the DG of APP tg mice compared with non-tg
mice, the DCX-positive cells detected in the APP tg mice also
displayed signiﬁcantly shorter DCX-positive processes
extending from the SGZ (Figures 6a, c, and e). These results
are consistent with our in vitro results showing that aberrant
CDK5 activation resulted in impaired neurite outgrowth in
cultured NPCs (Figure 1), and support the contention that
abnormally high levels of CDK5 activity might be detrimental
to neuronal maturation. Thus, we hypothesized that in vivo
modulation of CDK5 expression or activity might reverse the
neurogenic deﬁcits in the brains of APP tg mice with abnormal
CDK5 activation.
To investigate this possibility using a genetic approach,
APP tg mice were crossed with a line of mice that is
heterozygous deﬁcient for endogenous murine Cdk5 gene
(CDK5
þ/ ). As reported previously,
22 immunohistochemical
and immunoblot analyses showed that CDK5
þ/  mice
express B50% lower brain levels of CDK5 than wild-type
controls (Figures 5a, b, and e and Supplementary Figures 3A
and C). In support of previous studies using different models
of CDK5 ablation in the adult neurogenic niche,
23 the CDK5
heterozygous deﬁcient animals also exhibited a reduction in
DCX- and BrdU-positive cells in the DG of the hippocampus
compared with controls (Figures 5k, l, o, p, q, and t). These
results are consistent with the possibility that both abnormally
low or high levels of CDK5 activity are detrimental to neuronal
development.
In the offspring generated by crossing APP tg mice with
CDK5
þ/  mice (CDK5
þ/ /APP tg), the levels of CDK5 were
reducedinthebrainsofCDK5
þ/ /APPtgmicecomparedwith
APP tg mice, and were similar to levels in CDK5
þ/  mice
(Figures 5a–e and Supplementary Figures 3A and C).
Although immunohistochemical analysis revealed some
localized changes in p35/p25 immunoreactivity in the hippo-
campus (Figures 5f–j), no differences were observed in total
brain levels of p35 immunoreactivity by immunoblot (Supple-
mentary Figures 3A and D). Supporting the possibility that
reduced CDK5 activity was related to the reversal of
neurogenic deﬁcits in the CDK5
þ/ /APP animals compared
with APP tg mice, immunoblot analysis demonstrated that
CDK5activityinCDK5
þ/ /APPtgmicewasdownregulatedto
levelssimilartowild-typecontrols(SupplementaryFigure3B).
Remarkably, in the CDK5
þ/ /APP tg mice, there was a
signiﬁcant recovery of numbers of DCX- and BrdU-positive
cells compared with APP tg mice (Figures 5m–o and r–t).
Consistent with the in vitro studies (Figure 3), genetic
knockdown of CDK5 in APP tg mice resulted in a recovery
of DCX-positive processes extending from the SGZ of the
hippocampal DG (Figures 6a–e). Thus, normalization of
CDK5 activity levels may be beneﬁcial to the maintenance
of neuronal maturation in the adult hippocampus.
As CDK5-mediated neurotoxicity in AD has been
linked to abnormal cell cycle re-entry in mature neurons, we
sought to determine whether the neurogenesis effects in vivo
might be related to other cell cycle defects. Therefore, we
assessed the levels of other components of the cell cycle
(cyclin D1 and CDK2) in the brains of these animals by
immunoblot. Although there was a slight trend toward
increased cyclin D1 levels in APP tg animals, the differences
were not signiﬁcant, and no differences were detected in
CDK2 levels between the groups (Supplementary Figures 3A,
G, and H).
Figure 3 Downmodulation of abnormal CDK5 activity in vitro rescues neuronal maturation. Differentiating NPCs were pretreated on day 2 with the pharmacological
inhibitor Roscovitine (Rosco) or transfected with siRNA against CDK5 (siCDK5, 5nM), and then infected 6h later with adenovirus expressing p35, followed by treatment with
Ab on day 3 for 24h. On day 4, NPC-derived neural progeny were brieﬂy extracted and ﬁxed with glutaraldehyde for b-tubulin immunoﬂuorescence and neurite outgrowth
analysis. Cell nuclei were co-stained with DAPI reagent. (a–c) Compared with controls (a), uninfected NPC-derived neural progeny treated with Rosco (b) or siCDK5
(c) showed only a mild reduction in the lengths of b-tubulin-positive neurites. (d–f) NPC-derived neural progeny with p35/Ab treatment showed a notable decrease in the
lengths of b-tubulin-positive neurites (d); this was rescued by treatment with Rosco (e) or siCDK5 (f). (g) Neurite outgrowth measurements using NeuronJ showed a 50%
reduction in neurite lengths in p35/Ab-treated cells, and this effect was reversed in cultures pretreated with Rosco or transfected with siCDK5. Scale bar¼10mm. *Po0.05
compared with vehicle-treated controls by one-way ANOVA with post hoc Dunnett’s test (N¼3).
#Po0.05 compared with p35/Ab-treated NPCs by one-way ANOVA with
post hoc Tukey–Kramer test (N¼3)
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Cell Death and DiseaseNext, to determine whether rescued neurogenesis in
CDK5
þ/ /APP tg mice might be because of neuropathologi-
cal differences, additional immunoblot and immunohisto-
chemical studies were performed. We found that APP tg
miceandCDK5
þ/ /APPtgmiceshowedsimilarlevelsofAPP
expression and Ab production (Supplementary Figures 3A, E,
and F and Supplementary Figure 4). To examine general
neuronal integrity at lower power, immunolabeling studies
Figure 4 Characterization of expression patterns of the CDK5 signaling pathway in the neurogenic niche of the adult hippocampus in APP tg mice. Brain sections from
APP tg mice (9 months old) were double-labeled with antibodies against APP and CDK5 or p35, and CDK5 and the mature neuron marker microtubule-associated protein-2
(MAP2)ortheimmatureneuronmarkerdoublecortin(DCX).Allimagesarefromthedentategyrus(DG)ofthehippocampus.(a–c)Double-labelinganalysisofAPPandCDK5,
showing coexpression in cells of the DG (arrows), particularly in the granular cell layer (GCL). (d–f) Double-labeling analysis of APP and p35, showing coexpression of these
markersthroughouttheneuropiloftheDG.(g–i)Double-labelinganalysisofMAP2andCDK5,showingCDK5expressionlocalizedprimarilytotheGCLandsubgranularzone
(SGZ).MAP2wasdetectedmorepredominantlyinthemolecularlayer(ML).(j–l)Double-labelinganalysisofCDK5andDCXintheSGZandGCLregions,showingexpression
in and around cells in the SGZ. A subset of cells were co-immunolabeled with both CDK5 and DCX (arrows). Scale bar¼20mm
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Cell Death and Diseasewere performed with an antibody against NeuN, followed by
stereological image analysis (Supplementary Figure 5).
Neuronal density in the neocortex and hippocampus was
comparable among non-tg, CDK5
þ/ , and CDK5
þ/ /APP tg
mice, whereas in APP tg mice there was a reduction in the
numbers of NeuN-positive cells in layers II and III of the cortex
(Supplementary Figures 5A–E), and in the DG of the
hippocampus (Supplementary Figures 5F–J). Behavioral
studies showed that normalization of CDK5 activity in
CDK5
þ/ /APP tg mice was accompanied by improved
performance in the water maze test compared with APP tg
mice (Figures 7a and b). These results show that knockdown
of CDK5 in APP tg mice rescued both the neurogenic and
neurodegenerative alterations in APP tg mice.
CDK5 inhibition with Roscovitine in vivo ameliorates the
defects in neurogenesis in APP tg mice. To investigate
the possibility that modulation of CDK5 using a
pharmacological approach might have similar protective
effects on adult neurogenesis in APP tg mice, we
performed additional in vivo experiments where APP tg
mice were treated with the CDK5 inhibitor, Roscovitine.
APP tg mice that received intracerebral infusion with
Roscovitine or vehicle control displayed levels of CDK5 or
p35/p25 expression similar to vehicle-treated non-tg animals
(Figures 8a–h). Compared with non-tg controls, vehicle-
treated APP tg mice displayed a signiﬁcant reduction in DCX-
positive and BrdU-positive cells in the SGZ of the DG
(Figures 8i, j, l, m, n, and p). Remarkably, inhibition of
CDK5 activity with Roscovitine recovered the numbers of
DCX-positive and BrdU-positive cells in APP tg mice (Figures
8i–p). These results support the possibility that aberrant
activation of CDK5 in AD contributes to defective
neurogenesis, and inhibition of CDK5 might be useful in
therapeutic approaches aimed at rescuing the neurogenic
alterations associated with AD.
Figure 5 In vivo genetic modulation of CDK5 rescues neurogenic deﬁcits in the hippocampus of APP tg mice. Nine-month-old wild-type control mice (non-tg), CDK5
heterozygous deﬁcient (CDK5
þ/ ), APP tg mice, or crosses (CDK5
þ/ /APP) were treated with BrdU. Brain sections were processed for immunohistochemical analysis with
antibodiesagainstCDK5,p35/p25,doublecortin(DCX),orBrdU. Allimagesare fromthedentategyrusofthehippocampus.(a–e) Immunohistochemicalanalysisof thelevels
of CDK5 immunoreactivity in wild-type, CDK5
þ/ , APP tg mice, or CDK5
þ/ /APP crosses. (f–j) Immunohistochemical analysis of the levels of p35/p25 immunoreactivity in
wild-type, CDK5
þ/ , APP tg mice, or CDK5
þ/ /APP crosses. (k–o) Immunohistochemical analysis of the numbers of DCX-immunoreactive cells (arrows) in wild-type,
CDK5
þ/ ,APPtg mice,orCDK5
þ/ /APPcrosses.(p–t)ImmunohistochemicalanalysisofthenumbersofBrdU-immunoreactivecells(arrows)inwild-type,CDK5
þ/ ,APP
tgmice,orCDK5
þ/ /APPcrosses.Scalebar¼50mm.*Po0.05comparedwithwild-typecontrolsbyone-wayANOVAwithposthocDunnett’stest.
#Po0.05comparedwith
APP tg mice by one-way ANOVA with post hoc Tukey–Kramer test. N¼4 animals per group
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Cell Death and DiseaseDiscussion
In this study we found that in an in vitro model system of adult
hippocampal neurogenesis in AD, abnormal stimulation of the
CDK5/p35/p25 signaling pathway resulted in impaired ma-
turation of NPCs, as reﬂected by reduced neurite outgrowth
in NPC-derived neural progeny. These effects were rescued
by downmodulation of CDK5 activity by Roscovitine or siRNA
speciﬁcforCDK5.Similarly,intheAPPtgmousemodelofAD,
we found that deﬁcits in neurogenesis in the adult hippocam-
pus were reversed by genetic or pharmacological inhibition
of CDK5.
Previous studies have implicated CDK5 in embryonic
neuronal development
20 and neuroblast migration in the
cerebral cortex.
21,22 In healthy mature neurons, CDK5
regulates synaptic plasticity
28 and neurite outgrowth;
20 how-
ever, less is known about its role in adult neurogenesis.
Several recent studies have implicated CDK5 in the main-
tenance of a non-cycling state in postmitotic neurons.
29 This
function appears to be dependent on the subcellular localiza-
tion of CDK5, which is regulated by cell cycle stage
29 and
interactions with the cell cycle inhibitor p27,
30 among other
factors. Consistent with previous observations,
29 in this study
we have detected some CDK5 expression in both the nuclear
and cytoplasmic compartments in both in vitro and in vivo
models, which is likely a reﬂection of variability in cell cycle
stage of cycling NPCs and immature neural progeny.
Recent studies have implicated CDK5 in neuronal matura-
tion and dendritic development during the process of adult
neurogenesis.
6,23 Although loss of CDK5 activity does not
appear to alter neuronal fate, it severely disrupts dendritic
development of NPCs in vivo.
6,23 Targeted ablation of CDK5
expression in adult hippocampal NPCs reduces the numbers
ofDCX-positiveimmatureneuronsintheSGZ.
23Similarly,the
results of this study show in an alternative model of CDK5
deﬁciency that the numbers of hippocampal DCX- and BrdU-
positive cells were reduced.
It is important to note that although too little CDK5 activity is
detrimental to embryonic and adult neurogenesis,
6,22,23
pathological activation of CDK5 associated with AD has a
signiﬁcant negative impact as well. Notably, we observed
similar defects in neurogenesis in the brains of APP tg mice
that were rescued by CDK5 inhibition, suggesting that
abnormal CDK5 activation could reﬂect a loss of normal
Figure6 InvivogeneticmodulationofCDK5rescuesneuriteoutgrowthdefectsinthehippocampusofAPPtgmice.Brainsectionsfrom9-month-oldwild-typecontrolmice
(non-tg), CDK5 heterozygous deﬁcient (CDK5
þ/ ), APP tg mice, or crosses (CDK5
þ/ /APP) were processed for immunohistochemical analysis with an antibody against
doublecortin(DCX)anddevelopedwithDAB.Allimagesarefromthedentategyrusofthehippocampus.(a–d)ImmunohistochemicalanalysisofDCX-immunoreactivecellsin
the dentate gyrus of non-tg, CDK5
þ/ , APP tg mice, or CDK5
þ/ /APP crosses. Brackets denote representative DCX-immunoreactive processes extending from cells in the
SGZ that were measured. (e) Quantitative image analysis of the lengths of DCX-immunoreactive processes extending from DCX-immunoreactive cells located in the SGZ.
*Po0.05 compared with wild-type controls by one-way ANOVA with post hoc Dunnett’s test.
#Po0.05 compared with APP tg mice by one-way ANOVA with post hoc
Tukey–Kramer test. N¼4 animals per group
Figure 7 ImprovedcognitiveperformanceinthewatermazebehavioraltestinmicewithgeneticallyreducedCDK5levels.(aandb)Nine-montholdwild-typecontrolmice
(non-tg),CDK5heterozygousdeﬁcient(CDK5
þ/ ),APPtgmice,orcrosses(CDK5
þ/ /APPtg)weretrainedinthewatermaze,beginningwitha3-dayexposuretothevisible
platform.Micewerethentested for learningand memorywith the hiddenplatformfor 4 days,andmeasurements weretaken to determinethetime(in seconds)that micetook
to reach the platform (a), and distance swum before reaching the platform (b). *Po0.05 compared with wild-type controls by one-way ANOVA with post hoc Dunnett’s test.
#Po0.05 compared with APP tg mice by one-way ANOVA with post hoc Tukey–Kramer test. N¼4 animals per group
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Cell Death and Diseasefunction and/or a gain of atypical function; however, future
studies will be necessary to elucidate the mechanisms
involved. A previous review paper aptly labeled CDK5 as a
‘Jekyll and Hyde kinase’,
2 reﬂecting both the important
physiological role of CDK5 in development
22,28 and the
abnormal CDK5 activity associated with neurodegeneration
in the pathogenesis of AD.
9
Although physiological CDK5 activity is required for the
critical functions noted above, abnormal stimulation of CDK5
in the pathogenesis of AD has been shown to contribute to the
neurodegenerative process and mature neuronal cell death.
9
In this neurotoxic pathway, Ab triggers calcium inﬂux, which
activates calpain activity and subsequent cleavage of p35 to
p25, a stable activator of CDK5 that promotes the hyperphos-
phorylation of downstream substrates of CDK5.
9 In this
context, for this study we focused on the activation of this
pathway to further probe the role of CDK5 in adult
hippocampal neurogenesis and neuronal maturation in AD.
Our studies in an in vitro model of aberrant CDK5 activation in
adult neurogenesis in AD show that p35 overexpression
combined with Ab treatment promoted the generation of
abnormal neural progeny and impaired neurite outgrowth.
It was an unexpected ﬁnding that under conditions of
abnormal CDK5 activation in our in vitro NPC model, the
proportions of progeny coexpressing markers traditionally
associated with proliferation or neuronal differentiation stages
were more prominent than under control conditions. We
hypothesize that these disease-like conditions might arrest cells
in an early transitional state where expression of progenitor cell
markersmightbeprolongedoratypical,reﬂectinganimpairment
in the neuronal maturation process. In support of this possibility,
a previous study has shown that in the DG of AD brains,
progenitor cells fail to differentiate into mature microtubule-
associated protein-2 (MAP2)-positive neurons.
14
Figure 8 Roscovitine treatmentrescues neurogenic deﬁcitsinthehippocampusof APP tg mice.Brainsectionsfrom9-month-oldAPP tg miceandnon-tg controlstreated
with Roscovitine or vehicle control and BrdU were processed for immunohistochemical analysis with antibodies against CDK5, p35/p25, doublecortin (DCX), or BrdU.
All images are from the dentate gyrus of the hippocampus. (a–d) Analysis of CDK5 immunoreactivity in non-tg and APP tg mice treated with vehicle control or Roscovitine.
(e–h) Analysis of p35/p25 immunoreactivity in non-tg and APP tg mice treated with vehicle control or Roscovitine. (i–l) Analysis of DCX immunoreactivity and the numbers of
positivecellsinnon-tgandAPPtgmicetreatedwithvehiclecontrolorRoscovitine.(m–p)AnalysisofBrdUimmunoreactivityandnumbersofpositivecellsinnon-tgandAPPtg
micetreatedwithvehiclecontrolorRoscovitine.Scalebar¼50mm.*Po0.05comparedwithvehicle-treatednon-tgcontrolsbyone-wayANOVAwithposthocDunnett’stest.
N¼4 animals per group.
#Po0.05 compared with APP tg mice by one-way ANOVA with post hoc Tukey–Kramer test. N¼4 animals per group
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Cell Death and DiseaseFurther studies will be necessary to delineate the precise
mechanisms and downstream targets through which abnor-
mal CDK5 activation interferes with the maturation of NPCs in
AD. Several substrates of CDK5 are worth further investiga-
tion because a number of these are involved in cytoskeletal
development, and could be functionally related to neurite
outgrowth. Taken together, this study supports a role for
abnormal activation of CDK5 in impaired maturation of NPCs
in the adult hippocampus in AD. Therapeutic approaches
targeting at normalizing, but not eradicating, CDK5 activity
may prove useful in promoting the appropriate maturation of
hippocampal NPCs in AD.
Materials and Methods
NPC culture, neuronal differentiation assay, and live cell
imaging. Adult rat hippocampal NPCs (provided by F Gage, Salk Institute,
La Jolla, CA, USA) provide a useful model for studying adult hippocampal
neurogenesis. This in vitro model has been extensively characterized in several
previous studies where the phenotype and expression patterns of a variety of
lineage markers of neuronal progeny derived from these NPCs have been
examined in detail.
31,32 Moreover, their survival and differentiation has been
conﬁrmed after in vivo transplantation in the brain,
32 suggesting that these cells are
capable of undergoing neuronal maturation similar to endogenous NPCs.
Adult rat hippocampal NPCs were cultured routinely for expansion as previously
described,
26 with some modiﬁcations. Brieﬂy, cells were grown as monolayers on
poly-ornithine/laminin-coated plates in NPC basal media (DMEM/F-12 (Mediatech,
Manassas, VA, USA), 2mM L-glutamine, and 1% penicillin–streptomycin (all from
Invitrogen, Carlsbad, CA, USA)) supplemented with 1  B27 supplement (without
vitamin A) and 20ng/ml ﬁbroblast growth factor-2 (FGF2; Millipore, Temecula, CA,
USA). This media (NPC Growth media) was used to enhance growth conditions
for maximal proliferation of cells. For differentiation, cells were plated onto
poly-ornithine/laminin (Sigma-Aldrich, St. Louis, MO, USA)-coated plates or
coverslips in NPC growth media, and transferred the following day (day 0) to
NPC differentiation media (NPC basal media supplemented with 1  N2
supplement (Invitrogen), 1mM all-trans retinoic acid (Sigma-Aldrich), 5mM forskolin
(Sigma-Aldrich), and 1% FBS). Cells were differentiated for 4 days, with fresh NPC
differentiation media added at day 2. Live cell imaging of NPCs and NPC-derived
neural progeny in culture was performed on an Olympus (Center Valley, PA, USA)
IX70 inverted microscope. It should be noted that this differentiation procedure
generates heterogeneous cultures comprising predominantly immature neuronal
progeny with a minor fraction of cells expressing progenitor or glial cell markers,
and therefore we refer to the cells derived from the differentiation process as
‘NPC-derived neural progeny’.
Adaptation of the adult hippocampal NPC neural induction
protocol to model CDK5 activation in AD. To investigate the role of the
CDK5 signaling pathway in the differentiation of NPCs, we studied the effects of
activating this pathway in the adult rat hippocampal NPC model by utilizing a viral
vector expressing the CDK5 activator, p35. As Ab has been shown to abnormally
stimulate the activity of this pathway, p35-expressing differentiating cells were
treated in combination with exogenous Ab peptide. For this purpose, cells were
infected on day 2 of differentiation with adenovirus expressing human p35 or GFP
control (Vector Biolabs, Philadelphia, PA, USA) at a multiplicity of infection (MOI) of
30. Although p35 expression reﬂected a several-fold increase over endogenous
levels (Figure1a), this isconsistentwith a previousstudy investigating theeffects of
plasmid-drivenp35overexpressioninamatureneuronalcellline,wheresimilarhigh
levels of p35 were demonstrated with no off-target effects.
33 Following p35
expression, cells were treated on day 3 with freshly solubilized human Ab1 42 (1–
5mM; American Peptide, Sunnyvale, CA, USA), or reverse human Ab42 1 peptide
(1mM; American Peptide) as a control. Additional controls included vehicle
alone or a non-Ab amyloidogenic protein, human TTR (1mM; EMD Chemicals,
San Diego, CA, USA). At the conclusion of the in vitro experiments, cells were
lysed for immunoblot analysis, or cells on coverslips were ﬁxed in 4%
paraformaldehyde (PFA) in phosphate-buffered saline (PBS) for immunocyto-
chemical analysis.
For neurite outgrowth studies, a subset of cultured cells on coverslips were ﬁxed
in a solution containing glutaraldehyde, which better preserves the cytoskeleton for
optimalvisualizationofneuritesusingimmunoﬂuorescencewithanantibodyagainst
b-tubulin. For this purpose, a ﬁxation procedure was used essentially as previously
described by Desai and Mitchison (http://mitchison.med.harvard.edu/protocols/
gen1.html). Brieﬂy, media was gently aspirated from cells growing on glass
coverslips, and then cells were extracted for 30s in cytoskeletal buffer (CB, 80mM
PIPES pH 6.8, 1mM MgCl2, 4mM EGTA) containing 0.5% freshly added Triton-X
100. Glutaraldehyde (Electron Microscopy Sciences, Hatﬁeld, PA, USA) was
immediately added to the CB on the coverslips at a ﬁnal concentration of 0.5%.
Coverslips were incubated for 10min at 371C. Fixative was then removed and a
freshly prepared solution of 0.1% NaBH4 in PBS was added and samples were
incubated for 7min at room temperature to quench free glutaraldehyde. Coverslips
were washed at least three times in PBS to remove the NaBH4, and samples were
then processed for b-tubulin immunoﬂuorescence analysis.
Pharmacological treatments, siRNAknockdown, and analysisof
cell toxicity. For inhibition of the CDK5 signaling pathway, cells were treated at
day 2 of differentiation with either the pharmacological CDK5 inhibitor Roscovitine
(1–10mM, Calbiochem, San Diego, CA, USA) or transfected with siRNA against
CDK5 or control nontargeting ﬂuorescent-tagged siRNA (37.5–150ng; Qiagen,
Valencia, CA, USA) using the HiPerfect transfection reagent (Qiagen) according to
the manufacturer’s protocol. Additional experiments were performed in NPC-
derived neural progeny after 4 days of differentiation to assess potential toxicity of
the viral expression of p35 and Ab treatment using the LDH-based CytoTox Assay
according to the manufacturer’s instructions (Promega, Madison, WI, USA).
Animal models, treatments, and tissue processing. For studies of
CDK5 activation and neurogenesis in an animal model of AD, tg mice expressing
high levels of mutated human (h)APP751 under the control of the mThy-1 promoter
(mThy1-hAPP751)
34 were used. These tg mice produce high levels of Ab1 42, and
amyloidplaquesarefoundinthebrainatanearlyage(beginningat3months).
34To
study the effects of genetic CDK5 inhibition in vivo, Cdk5 heterozygous deﬁcient
micewereused(CDK5
þ/ ).
22FullablationofbothgenecopiesofCdk5(CDK5
 / )
inmiceisembryoniclethal,andhenceinordertostudyCdk5geneknockdowninthe
adult mouse brain, the CDK5
þ/  animals were used as a model of reduced CDK5
activity. CDK5
þ/  mice were kindly provided by the laboratory of Dr. Joseph
Gleeson (University of California at San Diego (UCSD)).
For in vivo studies of neurogenesis, 8-month-old non-tg, CDK5
þ/ , APP tg, or
CDK5
þ/ /APP tg crossed mice (N¼8 per group) received 5 injections (one per
day) with BrdU (Sigma-Aldrich) at 50mg/kg or vehicle control (saline) (N¼4 per
group, per treatment). After 1 month, mice were killed and their brains were
prepared for immunoblot and immunohistochemical analyses, and stereological
assessment of neurogenesis.
For pharmacological treatments, 8-month-old non-tg and APP tg animals (N¼8
per group) received intracerebral infusions of Roscovitine (Calbiochem) at a
concentration of 20mg/kg into the lateralventricle (N¼4 per group, per treatment).
For this purpose, mice were anesthetized, and under sterile conditions a 26-gauge
stainless steel cannula was implanted stereotaxically into the lateral ventricle using
thebregmaasareference(0.5mm;1.1mmlateral;depth3mm)andsecuredtothe
cranium using superglue. The cannula was connected via a 5mm coil of V3 vinyl
tubing (Biolab Products, Lake Havasu City, AZ, USA) to a model 1007D osmotic
minipump (Alzet, Cupertino, CA, USA) surgically placed subcutaneously beneath
theshoulder.Thesolutionsweredeliveredataﬂow rateof 0.5ml/hfor 2weeks.The
pump was left for an additional 2 weeks and mice were killed at 1 month after
the initiation of the infusions.
Behavioral studies. Brieﬂy, as previously described,
35 in order to evaluate
learning andmemory in theCDK5
þ/ /APPtg mice,the animals weretrained in the
watermaze,beginningwitha3-dayexposuretothevisibleplatform.Micewerethen
tested for learning and memory with the hidden platform for 4 days, followed by one
Visible Test trial and 1-day probe testing. In the memory portion of the water maze
behavioral test, the platform was removed (Probe test) to evaluate the time spent
(Time) and distance traveled (Distance) swimming in the target quadrant where the
platform was previously located. All experiments described were approved by the
animal subjects committee at the UCSD and were performed according to the NIH
recommendations for animal use.
Tissue processing. In accordance with the NIH guidelines for the humane
treatment of animals, mice were anesthetized with chloral hydrate and ﬂush-
perfusedtranscardiallywith0.9%saline.Brainswereremovedanddividedsagitally.
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sectioned at 40mm with a Vibratome 2000 (Leica Microsystems, Bannockburn,
IL, USA), whereas the other hemibrain was snap frozen and stored at  701C for
protein analysis. All experiments described were approved by the animal subjects
committee at the UCSD and were performed according to the NIH
recommendations for animal use.
Immunoblot analysis. For preparation of total cell lysates from cultured adult
rat hippocampal NPCs and NPC-derived neural progeny, adherent cells in culture
were lysed in buffer composed of 10mM Tris-HCl (pH 7.4), 150mM NaCl, 5mM
EDTA (TNE) containing 1% Triton-X 100 and fresh protease, and phosphatase and
calpain inhibitors to obtain total cell lysates. For preparation of homogenates from
mouse brains, brieﬂy as previously described,
36 0.1g of frozen tissue was
homogenized in 500ml of a detergent-free HEPES-based lysis buffer (1.0mM
HEPES, 5.0mM benzamidine, 2.0mM 2-mercaptoethanol, 3.0mM EDTA, 0.5mM
magnesium sulfate, 0.05% sodium azide; ﬁnal pH 8.8) that facilitates separation of
membraneandcytosolicfractions.Freshprotease,phosphatase,andcalpaininhibitor
cocktails (Calbiochem) were added to all lysis buffers. Following a brief centrifugation
step to clear nuclei and cell debris, total homogenates were then centrifuged for 1h at
100000r.p.m. at 41C. Supernatants were saved (cytosolic fraction) and the pellets
(membrane fraction) were resuspended in 500ml HEPES lysis buffer.
For immunoblot analysis of total cell lysates from NPC-derived neural progeny,
20mg of total protein from each sample was separated by gel electrophoresis on
4–12% Bis-Tris gels (Invitrogen) and blotted onto 0.45mm PVDF membranes
(Millipore). Immunoblots were blocked in a solution containing 5% BSA in PBS with
0.05% Tween-20 (BSA-PBST). Blots were then probed in primary antibody
solutions made up in BSA-PBST containing polyclonal antibodies against CDK5
(1:500, C-8, rabbit; Santa Cruz Biotechnology, Santa Cruz, CA, USA), p35/p25
(1:500, C-19, rabbit; Santa Cruz Biotechnology), or the immature neuronal marker
DCX (1:500, goat; Santa Cruz Biotechnology), or mouse monoclonal antibodies
againsttheimmatureneuronalmarkerb-IIItubulin(1:10000,Tuj1clone;Covance,
Princeton, NJ, USA), the NPC/radial glia marker S100-b (1:1000; Sigma-Aldrich),
the astroglial marker GFAP (1:1000; Millipore), the NPC marker nestin (1:1000;
Millipore), the proliferating cell marker PCNA (1:1000, PC10 clone; Santa Cruz
Biotechnology), the radial glial marker BLBP (1:1000; Millipore), or actin (1:2000,
C4 clone; Millipore) as a loading control as previously described.
34 In agreement
with several previous studies,
9,10,37 by immunoblot it was difﬁcult to consistently
detectthebandcorrespondingtop25intheinvitroNPCmodelsystem.Underbasal
conditions, only background immunoreactivity was detected in the region of 25kDa;
however, when cells were infected with adv-p35, a faint, diffuse band was visible at
a molecular weight of 25kDa (Figure 1a).
For immunoblot analysis of cytosolic and membrane fractions from brain
homogenates, 20mg of total protein from each sample was separated by gel
electrophoresisandimmunoblottedandblockedasdescribedforlysatesfromNPC-
derived neural progeny. Blots were then probed with rabbit polyclonal antibodies
against CDK5 (1:500, C-8; Santa Cruz Biotechnology), phosphorylated CDK5
(Tyr15, 1:500; Santa Cruz Biotechnology), p35/p25 (1:500, C-19; Santa Cruz
Biotechnology),cyclinD1(1:500;SantaCruzBiotechnology),CDK2(1:500;Santa
Cruz Biotechnology), or mouse monoclonal antibodies against full-length human
APP (1:1000, 6E10 clone; Signet Laboratories, Dedham, MA, USA), Ab (1:1000,
82E1 clone; Signet Laboratories), the immature neuronal marker b-III tubulin
(1:10000,Tuj1clone,Covance),oractin(1:2000,C4clone;Millipore)asaloading
control. All blots were then washed in PBS, incubated with secondary species-
speciﬁc antibodies (1:5000 in BSA-PBST), and visualized with enhanced
chemiluminescence (ECL; PerkinElmer, Waltham, MA, USA). Images were
obtained and semiquantitative analysis was performed with the VersaDoc gel
imaging system and Quantity One software (Bio-Rad, Hercules, CA, USA). All
signals were normalized to actin as a loading control, and expression levels were
calculated as ratios compared with vehicle-treated or wild-type controls.
Immunoprecipitation and kinase activity assay. For analysis of
CDK5 activity levels in cultured cells, a kinase activity assay was performed
essentially as previously described.
38 For this purpose, 300mg of total cell lysate
from NPC-derived neural progeny was incubated with 1mg of rabbit polyclonal
antibody against CDK5 (C-8; Santa Cruz Biotechnology) in a total volume of 500ml
CDK5 IP buffer (50mM Tris pH 7.5, 150mM NaCl, 1mM EDTA, and 1mM EGTA)
with freshly added protease, calpain, and phosphatase inhibitors for 1h at 41C with
gentle rotation. Then, 20ml of protein A (Roche, Basel, Switzerland) prewashed
beads slurry was added to the lysate, and samples were incubated for 3h at 41C
with gentle rotation. Samples were then centrifuged (12000r.p.m. for 30s in a
microcentrifuge) and washed three times with 1ml CDK5 IP buffer, with gentle
rotation for 10min at 41C between each wash. All supernatant was carefully
removed after the ﬁnal wash. Then, for the kinase activity assay, beads were
resuspended in a ﬁnal volume of 50ml of CDK5 kinase assay buffer (25mM Tris pH
7.5, 10mM MgCl2) containing freshly added 90mM ATP and 0.1mM histone H1
peptide (Promega). Samples were incubated for 30min at 301C, and then
transferred to wells in an all-white 96-well plate. To each sample, 50ml of Kinase-
Glo Plus reagent (Promega) was added, and luminescence values were measured
on a DTX 880 Multimode plate reader (Beckman Coulter, Brea, CA, USA). This
reagent reacts with the remaining ATP in each sample, and a standard curve of
serial dilutions of ATP in kinase buffer alone with Kinase-Glo reagent allowed
determination of the concentration of remaining ATP after the kinase reaction.
For assessment of CDK5 activity in mouse brain homogenates, levels of
phosphorylated (Tyr15) CDK5 were analyzed as a marker of CDK5 activation.
Previous studies have demonstrated that this modiﬁcation results in dramatically
increased CDK5 activity.
27 Therefore, relative kinase activity in mouse brains was
expressed as fold change in the levels of pCDK5 (Tyr15).
Immunocytochemical analysis. For analysis of levels of components of
the CDK5 signaling pathway and markers of neurogenesis in NPC-derived neural
progeny, adherent cells on coverslips were ﬁxed in 4% PFA in PBS, and then
processed for immunoﬂuorescence or immunocytochemical analysis with
diaminobenzidine (DAB). For immunoﬂuorescence, coverslips were blocked in
10% serum (Vector Laboratories, Burlingame, CA, USA), and then immunolabeled
with the rabbit polyclonal antibodies against CDK5 (1:1000, C-8; Santa Cruz
Biotechnology), p35 (1:1000, C-19; Santa Cruz Biotechnology), or the mouse
monoclonal antibodies against nestin (1:200; Millipore) or S100-b (1:250; Sigma-
Aldrich) detected with the Tyramide Signal Ampliﬁcation-Direct (Red) system (NEN
Life Sciences, Boston, MA, USA). For double-immunolabeling analysis, some
samples were co-labeled with a mouse monoclonal antibody against b-III tubulin
(1:250, Tuj1 clone; Covance) or a goat polyclonal antibody against the immature
neuronal marker DCX (1:100; Santa Cruz Biotechnology) detected with FITC-
conjugated secondary antibodies (1:75; Vector Laboratories). For
immunocytochemical analysis with DAB, coverslips were blocked and incubated
in primary mouse monoclonal antibody against b-III-tubulin (1:250, Tuj1 clone;
Covance) or goat polyclonal antibody against DCX (1:100; Santa Cruz
Biotechnology), and incubated with biotinylated secondary antibodies detected
with DAB.
For analysis of the levels of components of the CDK5 signaling pathway and
markers of neurogenesis in the brains of non-tg, CDK5
þ/  mice, or APP tg mice,
brain sections were processed for double-labeling immunoﬂuorescence or
immunocytochemical analysis with DAB. For immunoﬂuorescence, sections were
blocked in 10% serum (Vector Laboratories), and then immunolabeled with the
rabbit polyclonal antibodies against CDK5 (1:1000, C-8; Santa Cruz Biotechno-
logy) or p35/p25 (1:1000, C-19; Santa Cruz Biotechnology), detected with the
Tyramide Signal Ampliﬁcation-Direct (Red) system (NEN Life Sciences). Sections
were co-labeled with mouse monoclonal antibodies against human APP (8E5,
1:2000, courtesy of ELAN Pharmaceuticals, San Francisco, CA, USA), or the
mature neuronal marker MAP2 (1:250; Millipore), or the goat polyclonal antibody
against DCX (1:100; Santa Cruz Biotechnology), a marker of migrating
neuroblasts, detected with FITC-conjugated secondary antibodies (1:75; Vector
Laboratories). Single-labeling immunoﬂuorescence analysis was performed on
brain sections with antibodies against CDK5 and DCX as described for double-
labelingwithout asecondantibodystep.TheAbplaquesinsectionsfromthebrains
of mice studied were analyzed with an antibody against Ab (4G8, 1:500; Signet
Laboratories) detected with FITC-conjugated secondary antibodies (1:75; Vector
Laboratories). Fluorescent-labeled sections were mounted under glass coverslips
with ProLong Gold antifade reagent and imaged with a Zeiss  63 (N.A. 1.4)
objective on an Axiovert 35 microscope (Zeiss, Oberkochen, Germany) with an
attached MRC1024 laser scanning confocal microscope system (Bio-Rad).
36
For immunocytochemical analysis with DAB, sections were blocked and
incubatedin rabbitpolyclonal antibodiesagainstp35/p25(1:500,C-19; SantaCruz
Biotechnology), rat antibody against BrdU (1:100, rat monoclonal; AbD Serotec,
Raleigh, NC, USA), or primary mouse monoclonal antibody NeuN (1:500;
Millipore), and incubated with biotinylated secondary antibodies detected with DAB.
For sections immunostained for BrdU, pretreatments were performed essentially as
previously described.
39 DAB-immunostained sections were mounted with Entellan
and imaged with a digital Olympus microscope.
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experiments were performed twice to assess reproducibility. To conﬁrm the
speciﬁcity of primary antibodies, control experiments were performed where
sectionswere incubatedovernightin theabsenceof primaryantibody(deleted).For
all immunolabeling studies, assessment of the levels of immunoreactivity was
performed utilizing the Image-Pro Plus program (Media Cybernetics, Silver Spring,
MD, USA). For each mouse, a total of three sections (10 images per section) were
analyzed in order to estimate the average number of immunolabeled cells per unit
area (mm
2) or the average intensity of the immunoreactive signal (corrected pixel
intensity).
Neurite outgrowth studies. For b-tubulin immunoﬂuorescence and neurite
outgrowth studies, NPC-derived neural progeny growing on coverslips were ﬁxed
with glutaraldehyde and incubated with a mouse monoclonal primary anti-b-tubulin
antibody (1:250, clone B2.1; Sigma-Aldrich) for 1h at room temperature and
detected with FITC-conjugated secondary antibodies (1:75; Vector Laboratories).
b-Tubulin-labeled coverslips were mounted under glass coverslips with ProLong
Gold antifade reagent with DAPI (Invitrogen) and imaged with a Zeiss  63 (N.A.
1.4) objective on an Axiovert 35 microscope (Zeiss) with an attached MRC1024
laser scanning confocal microscope system (Bio-Rad).
36 For analysis of neurite
outgrowth of NPC-derived neural progeny immunolabeled with b-tubulin or DCX-
positivecellsin theDG of mouse brainsections, processeswere tracedandlengths
were measured using the ImageJ Program (NIH, Bethesda, MD, USA) with the
NeuronJ Plugin.
40
Quantitative analysis of neurogenesis in the hippocampus. For
this purpose, a systematic, random counting procedure, similar to the optical
disector, was used as described previously.
18 For the purpose of this study, the
morphometricanalysiswasfocusedontheSGZoftheDG.Thisareacorrespondsto
thelayer of NPCs located directly under the ﬁrst layer of mature granular cells in the
DG, which in addition to the SGZ, includes the granular cell layer (GCL) and the
molecular layer (ML). The analysis was centered on the SGZ because a previous
studyhasshownthatthisistheareamostconsistentlyaffectedinAPPtgmice.
17To
determine the number of BrdU-positive or DCX-positive cells in the SGZ of the
hippocampus, every sixth section (200-mm interval) of the left hemisphere was
selectedfromeachanimalandprocessedfor immunohistochemistry.Thereference
volume was determined by tracing the areas using a semiautomatic stereology
system (Stereoinvestigator; MicroBrightField, Colchester, VT, USA). Positive cells
were counted within a 60 60mm counting frame, which was spaced in a
300 300mm counting grid. Positive proﬁles that intersected the uppermost focal
plane (exclusion plane) or the lateral exclusion boundaries of the counting frame
were not counted. The total counts of positive proﬁles were multiplied by the ratio of
reference volume to sampling volume in order to obtain the estimated number of
positive cells for each structure. Results were expressed as fold change compared
with controls so that the scale is comparable in the studies of neurogenesis in both
human and mouse brains.
qRT-PCR analysis. RNA was puriﬁed from cultured cells or the hippocampus
fromcontrolandtgmiceusingtheRNeasyminikit(Qiagen).TotalRNAwasreverse
transcribed using iScript cDNA Synthesis kit (Bio-Rad) with 1mg of total RNA in
accordance with the manufacturer’s instructions. Quantitative PCR was performed
with primers speciﬁc for CDK5 or GAPDH as a housekeeping gene control (primer
assays; Qiagen) using the iCycler iQ Real-Time PCR Detection System (Bio-Rad).
Reactions were performed in a volume of 25ml using the iQ SYBR Green Supermix
(Bio-Rad) according to the manufacturer’s instructions.
Statistical analysis. All experiments were performed blind coded and in
triplicate. Values in the ﬁgures are expressed as means±S.E.M. To determine the
statistical signiﬁcance, values were compared using Student’s t-test, or one-way
ANOVA with post hoc Dunnett’s or Tukey–Kramer test. The differences were
considered to be signiﬁcant if P-values were o0.05.
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